HK1247119A1 - 一種治療方法和用於所述治療方法中的化合物 - Google Patents

一種治療方法和用於所述治療方法中的化合物

Info

Publication number
HK1247119A1
HK1247119A1 HK18106820.3A HK18106820A HK1247119A1 HK 1247119 A1 HK1247119 A1 HK 1247119A1 HK 18106820 A HK18106820 A HK 18106820A HK 1247119 A1 HK1247119 A1 HK 1247119A1
Authority
HK
Hong Kong
Prior art keywords
compounds
treatment
Prior art date
Application number
HK18106820.3A
Other languages
English (en)
Inventor
R‧H‧里奇
秦承雪
A‧克里斯托珀勒斯
P‧M‧塞克斯通
J‧B‧貝爾
Original Assignee
貝克心臟與糖尿病研究所
莫拿什大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015900336A external-priority patent/AU2015900336A0/en
Application filed by 貝克心臟與糖尿病研究所, 莫拿什大學 filed Critical 貝克心臟與糖尿病研究所
Publication of HK1247119A1 publication Critical patent/HK1247119A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18106820.3A 2015-02-04 2018-05-25 一種治療方法和用於所述治療方法中的化合物 HK1247119A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015900336A AU2015900336A0 (en) 2015-02-04 A method of treatment and compounds for use therein
PCT/AU2016/050065 WO2016123672A1 (en) 2015-02-04 2016-02-04 A method of treatment and compounds for use therein

Publications (1)

Publication Number Publication Date
HK1247119A1 true HK1247119A1 (zh) 2018-09-21

Family

ID=56563241

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106820.3A HK1247119A1 (zh) 2015-02-04 2018-05-25 一種治療方法和用於所述治療方法中的化合物

Country Status (6)

Country Link
US (1) US10328075B2 (zh)
EP (1) EP3253388A4 (zh)
CN (1) CN107847503A (zh)
AU (1) AU2016214975A1 (zh)
HK (1) HK1247119A1 (zh)
WO (1) WO2016123672A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892008A1 (ru) 2016-04-21 2019-06-28 Астросайт Фармасьютикалс, Инк. Соединения и способы лечения неврологических и сердечно-сосудистых состояний
AU2017348182A1 (en) * 2016-10-26 2019-05-16 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
CN112218638A (zh) 2018-02-09 2021-01-12 阿斯特罗赛特制药公司 用于治疗成瘾和相关病症的化合物和方法
WO2020069068A1 (en) 2018-09-26 2020-04-02 Astrocyte Pharmaceuticals, Inc. Polymorphic compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074069A2 (en) * 2002-03-07 2003-09-12 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with the n-formyl peptide receptor 1 (fpr 1)
AU2011270872A1 (en) 2010-06-24 2013-01-31 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
CA2819457A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
US8729096B2 (en) * 2012-02-16 2014-05-20 Allergan, Inc. Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators

Also Published As

Publication number Publication date
EP3253388A1 (en) 2017-12-13
WO2016123672A1 (en) 2016-08-11
EP3253388A4 (en) 2018-11-21
US10328075B2 (en) 2019-06-25
US20180092917A1 (en) 2018-04-05
AU2016214975A1 (en) 2017-08-10
CN107847503A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
HK1251614A1 (zh) 用於惡性腫瘤的治療的方法
HK1252568A1 (zh) 一種治療方法
GB201514756D0 (en) Compound and method of use
HK1248552A1 (zh) 使用川地匹坦的治療方法
GB201514760D0 (en) Compounds and method of use
PL3297975T3 (pl) Sposób kompleksowej utylizacji fosfogipsów
GB201609786D0 (en) Compounds and method of use
GB201410116D0 (en) Method of treatment
HK1252692A1 (zh) 治療或者預防蛋白質構象病的方法
EP3684342C0 (en) TREATMENT PROCEDURES
HK1247818A1 (zh) 治療疾病的方法
SG10201912688YA (en) A method of treatment
GB201706406D0 (en) Method of treatment
IL253028A0 (en) treatment method
HK1247119A1 (zh) 一種治療方法和用於所述治療方法中的化合物
GB201815588D0 (en) Method of treatment
GB201521886D0 (en) A method of treating a well
GB201602802D0 (en) Method of treatment
HK1250243A1 (zh) 治療方法
IL248847A0 (en) Dosertalin dosage and method for treating adhd
GB201806609D0 (en) A method of treatment and prognosis
GB201512139D0 (en) Methods of treatment
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment
AU2015900336A0 (en) A method of treatment and compounds for use therein